These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
185 related articles for article (PubMed ID: 16189155)
1. Melanoma inhibitor of apoptosis protein is expressed differentially in melanoma and melanocytic naevus, but similarly in primary and metastatic melanomas. Gong J; Chen N; Zhou Q; Yang B; Wang Y; Wang X J Clin Pathol; 2005 Oct; 58(10):1081-5. PubMed ID: 16189155 [TBL] [Abstract][Full Text] [Related]
2. Cytoplasmic beta-catenin is lacking in a subset of melanoma-associated naevi, but is detectable in naevus-associated melanomas: potential implications for melanoma tumorigenesis? De Panfilis G; Ferrari D; Santoro S; Ricci R; Lombardi M; Pedrazzi G; Pepe C; Cortelazzi C; Santini M Br J Dermatol; 2009 Mar; 160(3):600-8. PubMed ID: 19183173 [TBL] [Abstract][Full Text] [Related]
3. In situ expression patterns of melanoma-inhibiting activity (MIA) in melanomas and breast cancers. Bosserhoff AK; Moser M; Hein R; Landthaler M; Buettner R J Pathol; 1999 Mar; 187(4):446-54. PubMed ID: 10398105 [TBL] [Abstract][Full Text] [Related]
4. Aberrant expression and potency as a cancer immunotherapy target of inhibitor of apoptosis protein family, Livin/ML-IAP in lung cancer. Hariu H; Hirohashi Y; Torigoe T; Asanuma H; Hariu M; Tamura Y; Aketa K; Nabeta C; Nakanishi K; Kamiguchi K; Mano Y; Kitamura H; Kobayashi J; Tsukahara T; Shijubo N; Sato N Clin Cancer Res; 2005 Feb; 11(3):1000-9. PubMed ID: 15709165 [TBL] [Abstract][Full Text] [Related]
5. Cytokeratin expression in malignant melanoma: potential application of in-situ hybridization analysis of mRNA. Chen N; Gong J; Chen X; Xu M; Huang Y; Wang L; Geng N; Zhou Q Melanoma Res; 2009 Apr; 19(2):87-93. PubMed ID: 19190520 [TBL] [Abstract][Full Text] [Related]
6. Gene expression patterns in melanocytic cells: candidate markers for early stage and malignant transformation. Meije CB; Hakvoort TB; Swart GW; Westerhof W; Lamers WH; Das PK J Pathol; 2002 Jan; 196(1):51-8. PubMed ID: 11748642 [TBL] [Abstract][Full Text] [Related]
8. E-cadherin/catenin complex in benign and malignant melanocytic lesions. Silye R; Karayiannakis AJ; Syrigos KN; Poole S; van Noorden S; Batchelor W; Regele H; Sega W; Boesmueller H; Krausz T; Pignatelli M J Pathol; 1998 Dec; 186(4):350-5. PubMed ID: 10209482 [TBL] [Abstract][Full Text] [Related]
9. Expression of p53-induced apoptosis effector PERP in primary uveal melanomas: downregulation is associated with aggressive type. Paraoan L; Gray D; Hiscott P; Ebrahimi B; Damato B; Grierson I Exp Eye Res; 2006 Oct; 83(4):911-9. PubMed ID: 16784742 [TBL] [Abstract][Full Text] [Related]
10. Microphthalmia-associated transcription factor is a critical transcriptional regulator of melanoma inhibitor of apoptosis in melanomas. Dynek JN; Chan SM; Liu J; Zha J; Fairbrother WJ; Vucic D Cancer Res; 2008 May; 68(9):3124-32. PubMed ID: 18451137 [TBL] [Abstract][Full Text] [Related]
11. Inducible nitric oxide synthase expression in benign and malignant cutaneous melanocytic lesions. Massi D; Franchi A; Sardi I; Magnelli L; Paglierani M; Borgognoni L; Maria Reali U; Santucci M J Pathol; 2001 Jun; 194(2):194-200. PubMed ID: 11400148 [TBL] [Abstract][Full Text] [Related]
13. Expression and activation of matrix metalloproteinase-2 (MMP-2) and its co-localization with membrane-type 1 matrix metalloproteinase (MT1-MMP) correlate with melanoma progression. Hofmann UB; Westphal JR; Zendman AJ; Becker JC; Ruiter DJ; van Muijen GN J Pathol; 2000 Jul; 191(3):245-56. PubMed ID: 10878545 [TBL] [Abstract][Full Text] [Related]
14. The effect of the sun on expression of beta-catenin, p16 and cyclin d1 proteins in melanocytic lesions. Demirkan NC; Kesen Z; Akdag B; Larue L; Delmas V Clin Exp Dermatol; 2007 Nov; 32(6):733-9. PubMed ID: 17868395 [TBL] [Abstract][Full Text] [Related]
15. Cadherin expression in melanocytic naevi and malignant melanomas. Cowley GP; Smith ME J Pathol; 1996 Jun; 179(2):183-7. PubMed ID: 8758211 [TBL] [Abstract][Full Text] [Related]
16. Macrophage migration inhibitory factor protein and mRNA expression in cutaneous melanocytic tumours. Miracco C; De Nisi MC; Arcuri F; Cosci E; Pacenti L; Toscano M; Lalinga AV; Biagioli M; Rubegni P; Vatti R; Maellaro E; Del Bello B; Massi D; Luzi P; Tosi P Int J Oncol; 2006 Feb; 28(2):345-52. PubMed ID: 16391788 [TBL] [Abstract][Full Text] [Related]
17. Overexpression of Lerk-5/Eplg5 messenger RNA: a novel marker for increased tumorigenicity and metastatic potential in human malignant melanomas. Vogt T; Stolz W; Welsh J; Jung B; Kerbel RS; Kobayashi H; Landthaler M; McClelland M Clin Cancer Res; 1998 Mar; 4(3):791-7. PubMed ID: 9533549 [TBL] [Abstract][Full Text] [Related]
19. Differential expression of heat shock protein 105 in melanoma and melanocytic naevi. Muchemwa FC; Nakatsura T; Fukushima S; Nishimura Y; Kageshita T; Ihn H Melanoma Res; 2008 Jun; 18(3):166-71. PubMed ID: 18477890 [TBL] [Abstract][Full Text] [Related]
20. Inhibitor of apoptosis proteins gene expression and its correlation with prognostic factors in primary and metastatic uveal melanoma. Lederman M; Meir T; Zeschnigk M; Pe'er J; Chowers I Curr Eye Res; 2008 Oct; 33(10):876-84. PubMed ID: 18853322 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]